Outcomes of Lung Transplantation for Cystic Fibrosis in the Setting of Extensively Drug-Resistant Organisms
- 3 June 2019
- journal article
- research article
- Published by SAGE Publications in Progress in Transplantation
- Vol. 29 (3) , 220-224
Abstract
Introduction: Since the largest study on extensively drug-resistant organisms and lung transplantation in patients with cystic fibrosis, there have been innovations and advancements in the treatment of Pseudomonas aeruginosa. Research Question: What differences exist for patients with cystic fibrosis with a history of extensively drug-resistant infections who undergo lung transplantation despite treatment advances with antimicrobial therapy? Study Design: Two-center, retrospective, cohort study conducted in 44 patients with cystic fibrosis chronically infected with extensively drug-resistant organisms who received a lung transplant from January 2008 through August 2016. Patients in the resistant cohort were chronically infected with pan-resistant P aeruginosa, polymyxin-sensitive only, or sensitive to 2 antibiotic classes (polymyxin plus one other); remaining patients with more susceptible P aeruginosa or no P aeruginosa remained in the control cohort. The primary outcome is a composite of patient survival, retransplantation, chronic lung allograft dysfunction, and acute rejection 12 months posttransplant. Categorical variables were analyzed using χ2 testing. The independent samples t test was utilized for continuous variables. Results: There was no difference in the primary outcome (40% vs 37%, P = .831). Differences between patient survival (84% vs 95%, P = .487), the incidence of acute rejection (20% vs 33%, P = .323), and the incidence of chronic lung allograft rejection (12% vs 5%, P = .441) were not different between groups. Discussion: Recipients chronically infected with an extensively resistant P aeruginosa had similar outcomes compared to those infected with more sensitive organisms.Keywords
This publication has 20 references indexed in Scilit:
- The evolution of lung transplantation for cystic fibrosis: A 2017 updateJournal of Cystic Fibrosis, 2017
- Clinical and demographic factors associated with post–lung transplantation survival in individuals with cystic fibrosisThe Journal of Heart and Lung Transplantation, 2015
- A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung TransplantationThe Journal of Heart and Lung Transplantation, 2015
- Impact of Multidrug-Resistant Organisms on Patients Considered for Lung TransplantationInfectious Disease Clinics of North America, 2013
- A survey of the utilization of anti‐pseudomonal beta‐lactam therapy in cystic fibrosis patientsPediatric Pulmonology, 2011
- Survival of Lung Transplant Patients With Cystic Fibrosis Harboring Panresistant Bacteria Other Than Burkholderia cepacia, Compared With Patients Harboring Sensitive BacteriaThe Journal of Heart and Lung Transplantation, 2007
- The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centreJournal of Hospital Infection, 2004
- Survival Effect of Lung Transplantation Among Patients With Cystic FibrosisJAMA, 2001
- The Effects of Panresistant Bacteria in Cystic Fibrosis Patients on Lung Transplant OutcomeAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Adverse Effects of Sodium ColistimethateAnnals of Internal Medicine, 1970